Clinical Trial Update: Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) [Phase 2]

View source ↗

Summary

Phase 2 extension study evaluating long-term effects of ACE-083 in facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease types 1 and X (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Charcot-marie-tooth Disease
• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• ACE-083

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-06-02